Back to results
US 2018/0008669 A1Published application
Id4 protein restores wild type p53 activity
AssigneeClark Atlanta University
InventorsJaideep Chaudhary, Divya Patel, Ashley E. Knowell
Life of this patent
Estimating the term…
Abstract
A compound and method for treating cancer, in particular prostate cancer. Id4 reverts mutant p53 activity to its wild type physiological status and activity. Id4 or its peptidemimatics are used to revert mutant p53 to wild type p53, restoring its tumor suppressor activity.
Claims18
1-2. (canceled)
A method of treating cancer in a patient having mutant p53, the method comprising,
- delivering an inhibitor of differentiation protein 4 (Id4) to the patient so that the Id4 allows modification of mutant p53 to restore its wild type p53 functionality, wherein the mutant p53 has a mutation in the DNA binding domain (DBD).
8-9. (canceled)
A method of treating cancer in a patient having mutant p53, the method comprising,
- delivering a nucleic acid encoding an inhibitor of differentiation protein 4 (Id4) to the patient to increase the level of expression of Id4 so that the Id4 allows modification of mutant p53 to restore its wild type p53 functionality, wherein the mutant p53 has a mutation in the DNA binding domain (DBD).
A method of treating cancer in a patient having mutant p53, the method comprising,
- delivering an inhibitor of differentiation protein 4 (Id4) to the patient so that the Id4 allows modification of mutant p53 to restore its wild type p53 functionality,
- wherein the mutations are P223L and V274F.
Dependencies are inferred from the claim text.